Trivalent Chromium Treatment for Rheumatoid Arthritis

Alexandria University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: Trivalent chromium versus synthetic and/ or biological DMARDs

Study type: Interventional

Funder types: Other

Identifiers

NCT05545020

Trivalent chromium treatment

040457 (Registry Identifier)

Details and patient eligibility

About

Trivalent chromium has shown good results in abolishing inflammation and had a successful result in treating animal model of rheumatoid arthritis. In addition to that, trivalent chromium lacks many side effects which are related to the already known medications of the disease.

So this study aims to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients.

Full description

Rheumatoid arthritis is a debilitating autoimmune disease which is treated by medications that have many side effects. Trivalent chromium, a naturally occurring element with regulatory effects on blood sugar, has shown anti-inflammatory properties in many studies and has shown a good response at alleviation of rheumatoid arthritis in the disease animal model. For these reasons trivalent chromium should be tried in rheumatoid arthritis patients.

Enrollment: 60 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• rheumatoid arthritis

Exclusion criteria

• other autoimmune diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Trivalent chromium

Active Comparator group

Description:

A dietary supplement already available in market one of its known uses is to control diabetes.

Treatment:

Drug: Trivalent chromium versus synthetic and/ or biological DMARDs

Immunesuppressants

Active Comparator group

Description:

Synthetic and/ or biological DMARDs

Treatment:

Drug: Trivalent chromium versus synthetic and/ or biological DMARDs